Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
- 1 April 2011
- journal article
- review article
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 32 (2) , 88-111
Abstract
No abstract availableKeywords
This publication has 300 references indexed in Scilit:
- Tumorigenic and adhesive properties of heparanaseSeminars in Cancer Biology, 2010
- Small Molecule Inhibitors of the Neuropilin-1 Vascular Endothelial Growth Factor A (VEGF-A) InteractionJournal of Medicinal Chemistry, 2010
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Angiogenesis, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancerHuman Pathology, 2008
- Vascular permeability, vascular hyperpermeability and angiogenesisAngiogenesis, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Autocrine VEGF Signaling Is Required for Vascular HomeostasisCell, 2007
- Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesisExperimental Cell Research, 2006
- Failure of blood-island formation and vasculogenesis in Flk-1-deficient miceNature, 1995